THE PURPOSE of this paper is to present data on the treatment of polycythemia vera with triethylene melamine (T. E. M.), based on the study of 30 cases followed for an average period of more than one year. Triethylene melamine, a compound which has nitrogen-mustard-like action, has the advantage that it is effective upon oral administration. The development of triethylene melamine, its pharmacological properties, and its use in patients with lymphomas, leukemia, and various carcinomas have been extensively discussed in papers by Karnofsky and associates1 and Wright and co-workers.2 Because of its ease of administration and its depressant effects upon hematopoiesis, which appear to resemble those of nitrogen mustard (methyl-bis or tris [β-choroethyl] amine hydrochloride) and x-irradiation,3 it appeared that triethylene melamine might be of value in the treatment of polycythemia vera.
Emphasis upon the treatment of polycythemia by bone marrow inhibition is largely derived from the work of Lawrence,4
ROSENTHAL N, ROSENTHAL RL. TREATMENT OF POLYCYTHEMIA VERA WITH TRIETHYLENE MELAMINE: Summary of Thirty Cases. AMA Arch Intern Med. 1952;90(3):379–388. doi:10.1001/archinte.1952.00240090100008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: